VEGFR2 protein (Fc Chimera)
- Known as:
- VEGFR2 protein (Fc Chimera)
- Catalog number:
- 30r-av017
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- VEGFR2 protein ( Chimera)
Related genes to: VEGFR2 protein (Fc Chimera)
- Gene:
- KDR NIH gene
- Name:
- kinase insert domain receptor
- Previous symbol:
- -
- Synonyms:
- FLK1, VEGFR, VEGFR2, CD309
- Chromosome:
- 4q12
- Locus Type:
- gene with protein product
- Date approved:
- 1991-07-10
- Date modifiied:
- 2019-04-23
Related products to: VEGFR2 protein (Fc Chimera)
Related articles to: VEGFR2 protein (Fc Chimera)
- The treatment of advanced hormone receptor-positive (HR+) breast cancer has seen relevant changes in last years. However, bevacizumab remains an option when combined with paclitaxel, but no certified pharmacogenetic profiles are now usable for the prediction of its response in breast cancer patients. This study aimed to explore the pharmacogenetic interactions among single nucleotide polymorphisms (SNPs) of genes involved in the angiogenic process and their impact on progression-free survival (PFS) and overall survival (OS) in hormone receptor-positive (HR+) metastatic breast cancer subjects administered with bevacizumab plus paclitaxel, or with paclitaxel alone (clinicaltrial.gov identifier NCT01935102). - Source: PubMed
Publication date: 2026/04/22
Coltelli LuigiOrlandi PaolaFinale ChiaraMusettini GiannaMasini Luna ChiaraScalese MarcoSoria GiuliaSartori ElenaNodari YleniaArrighi GiadaBandini AriannaBanchi MartaTacchi CostanzaTang DonghaoSalvadori BarbaraTanganelli LuciaGiovannelli SimonaPistelli MircoCupini SamantaLucchesi MaurizioCosimi AlessandroLorenzini GiuliaBiasco ElisaCaparello ChiaraAcconci GiuliaFontana EloiseBona EleonoraFarnesi AzzurraPellino AntonioMarini AndreaDe Maio ErmelindaStasi IreneBarbara CeciliaSammarco EnricoRosada JavierAllegrini GiacomoBocci Guido - Vascular endothelial growth factor receptor 2 (VEGFR2) is a critical therapeutic target in hepatocellular carcinoma (HCC) due to its role in angiogenesis and tumor progression. While several inhibitors are currently used, clinical utility is often limited by resistance and adverse effects, necessitating the discovery of novel therapeutic agents. The aim of this study was to identify and characterize novel, highly effective VEGFR2 inhibitors using an integrated computational pipeline to advance the development of new HCC treatments. - Source: PubMed
Publication date: 2026/04/22
Yasmeen FarzanaManan AbdulKim WookChoi Sangdun - There are relatively well-substantiated concepts regarding the differences in the clinical course of metastatic colorectal cancer depending on the primary tumor localization: right- and left-sided (including rectal). However, many clinical trials demonstrate clear differences in the selected efficacy of adjuvant chemotherapy in the treatment of rectal versus colon cancer. We hypothesize that there are significant differences in long-term outcomes between patients with metastatic rectal cancer (RC) and those with left-sided colon cancer (LSCC) that may depend on the genetic profile of the primary tumor. - Source: PubMed
Publication date: 2026/04/15
Semenov N NZhukova L GYakovlev V A - Inhibition of the VEGF/VEGFR-2 pathway is a validated strategy to suppress tumor angiogenesis and progression; however, long-term use of several VEGFR-2 tyrosine kinase inhibitors is limited by resistance and systemic toxicity. Here, a series of novel indolinone-matrine hybrids were designed and synthesized via a molecular hybridization strategy. The antiproliferative activities were evaluated against human hepatocellular carcinoma (HCC) cell lines (HepG-2, HuH7, and MHCC97H). Among them, J9 showed the most potent activity with IC values of 5.81, 2.14, and 3.03 μM, respectively, and relatively low cytotoxicity toward HEK-293 cells (IC = 27.90 μM) and HL7702 cells (IC50 = 52.23 μM). In HuH7 cells, J9 significantly inhibited colony formation and migration, induced G1-phase arrest, and promoted apoptosis in a dose-dependent manner. Western blot analysis indicated that J9 treatment was associated with downregulation of VEGFR-2 and activation of caspase-dependent apoptosis (increased cleaved caspase-3 and cleaved PARP). Moreover, J9 inhibited VEGFR-2 kinase in vitro (IC = 253.51 ± 1.21 nM), and docking/MD simulations suggested stable binding within the VEGFR-2 ATP-binding pocket. Collectively, J9 represents a promising matrine-derived antitumor candidate with potential VEGFR-2-targeting activity. - Source: PubMed
Wang ZiyiWei YongquanXing ZexuJiang LiheWang Lisheng - The peach-potato aphid, Myzus persicae Sulzer (Hemiptera: Aphididae), is among the most destructive and adaptable agricultural pests worldwide, known for its ability to colonize hundreds of host plants and transmit numerous plant viruses. Moreover, it has evolved resistance to more insecticide classes and active ingredients than any other known arthropod pest, making it a key model for studying the evolution of resistance. This review synthesizes the biochemical, genetic, and ecological mechanisms underpinning this adaptability. We trace the historical and contemporary development of resistance to organophosphates, carbamates, pyrethroids, neonicotinoids, sulfoximines, ketoenols, and other insecticides, highlighting how metabolic detoxification by cytochrome P450 monooxygenases, carboxylesterases, glutathione S-transferases (GSTs), and uridine diphosphate-glycosyltransferases (UDPGTs) interacts with target-site mutations such as modified acetylcholinesterase (MACE), knockdown resistance (kdr), super-kdr, R81T, and acetyl-CoA carboxylase (ACC) substitutions. We also examine the regulation of these pathways through gene amplification, transcriptional plasticity, and inducible responses, while emphasizing fitness trade-offs that shape resistance dynamics in the field. By integrating these diverse perspectives, this review goes beyond cataloguing mechanisms to provide a comprehensive framework that explains how multi-resistant clones of M. persicae emerge and persist. We further discuss the implications of composite genotypes for resistance monitoring and management, and outline future directions including molecular diagnostics, synergists targeting detoxification enzymes, and integrated pest management strategies. Together, these insights underscore the urgent need for sustainable, informed approaches that account for genetic and biochemical dimensions of resistance to preserve the efficacy of current and future insecticides against this globally significant pest. - Source: PubMed
Publication date: 2026/03/03
Ali JaminTonğa AdilKhan Khalid AliOberemok VolYusuf Abdullahi AhmedChen Rizhao